vs
Northfield Bancorp, Inc.（NFBK）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Northfield Bancorp, Inc.的1.7倍（$69.8M vs $41.3M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -1545.5%，领先1929.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 12.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 15.0%）
诺斯菲尔德银行控股公司是总部位于美国的区域性银行机构，主要服务美国东北部市场，面向个人消费者、中小企业及本地社区客户提供储蓄存款、住房贷款、商业信贷、财富管理等多元银行服务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
NFBK vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.7倍
$41.3M
营收增速更快
RIGL
高出8.5%
12.7%
净利率更高
RIGL
高出1929.6%
-1545.5%
两年增速更快
RIGL
近两年复合增速
15.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.3M | $69.8M |
| 净利润 | $-27.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | -1263.3% | 33.2% |
| 净利率 | -1545.5% | 384.0% |
| 营收同比 | 12.7% | 21.2% |
| 净利润同比 | -343.6% | 1769.2% |
| 每股收益（稀释后） | $-0.68 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NFBKRIGL
| Q4 25 | $41.3M | $69.8M | ||
| Q3 25 | $39.2M | $69.5M | ||
| Q2 25 | $38.9M | $101.7M | ||
| Q1 25 | $34.8M | $53.3M | ||
| Q4 24 | $36.7M | $57.6M | ||
| Q3 24 | $31.8M | $55.3M | ||
| Q2 24 | $31.5M | $36.8M | ||
| Q1 24 | $31.3M | $29.5M |
净利润NFBKRIGL
| Q4 25 | $-27.4M | $268.1M | ||
| Q3 25 | $10.8M | $27.9M | ||
| Q2 25 | $9.6M | $59.6M | ||
| Q1 25 | $7.9M | $11.4M | ||
| Q4 24 | $11.3M | $14.3M | ||
| Q3 24 | $6.5M | $12.4M | ||
| Q2 24 | $6.0M | $-1.0M | ||
| Q1 24 | $6.2M | $-8.2M |
毛利率NFBKRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率NFBKRIGL
| Q4 25 | -1263.3% | 33.2% | ||
| Q3 25 | 37.7% | 40.9% | ||
| Q2 25 | 35.6% | 60.1% | ||
| Q1 25 | 31.0% | 23.9% | ||
| Q4 24 | 38.0% | 28.9% | ||
| Q3 24 | 27.9% | 25.4% | ||
| Q2 24 | 29.1% | 1.2% | ||
| Q1 24 | 27.2% | -23.6% |
净利率NFBKRIGL
| Q4 25 | -1545.5% | 384.0% | ||
| Q3 25 | 27.4% | 40.2% | ||
| Q2 25 | 24.6% | 58.6% | ||
| Q1 25 | 22.6% | 21.5% | ||
| Q4 24 | 30.7% | 24.9% | ||
| Q3 24 | 20.5% | 22.5% | ||
| Q2 24 | 18.9% | -2.8% | ||
| Q1 24 | 19.9% | -27.9% |
每股收益（稀释后）NFBKRIGL
| Q4 25 | $-0.68 | $14.11 | ||
| Q3 25 | $0.27 | $1.46 | ||
| Q2 25 | $0.24 | $3.28 | ||
| Q1 25 | $0.19 | $0.63 | ||
| Q4 24 | $0.27 | $0.82 | ||
| Q3 24 | $0.16 | $0.70 | ||
| Q2 24 | $0.14 | $-0.06 | ||
| Q1 24 | $0.15 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $164.0M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $690.1M | $391.5M |
| 总资产 | $5.8B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资NFBKRIGL
| Q4 25 | $164.0M | $155.0M | ||
| Q3 25 | $131.7M | $137.1M | ||
| Q2 25 | $97.6M | $108.4M | ||
| Q1 25 | $101.7M | $77.1M | ||
| Q4 24 | $167.7M | $77.3M | ||
| Q3 24 | $232.9M | $61.1M | ||
| Q2 24 | $153.5M | $49.1M | ||
| Q1 24 | $238.8M | $49.5M |
总债务NFBKRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $666.4M | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益NFBKRIGL
| Q4 25 | $690.1M | $391.5M | ||
| Q3 25 | $719.6M | $117.6M | ||
| Q2 25 | $710.3M | $81.9M | ||
| Q1 25 | $711.1M | $18.6M | ||
| Q4 24 | $704.7M | $3.3M | ||
| Q3 24 | $699.6M | $-14.6M | ||
| Q2 24 | $693.0M | $-29.9M | ||
| Q1 24 | $698.4M | $-31.7M |
总资产NFBKRIGL
| Q4 25 | $5.8B | $513.6M | ||
| Q3 25 | $5.7B | $242.5M | ||
| Q2 25 | $5.7B | $206.7M | ||
| Q1 25 | $5.7B | $176.0M | ||
| Q4 24 | $5.7B | $164.0M | ||
| Q3 24 | $5.7B | $139.4M | ||
| Q2 24 | $5.7B | $128.4M | ||
| Q1 24 | $5.9B | $126.5M |
负债/权益比NFBKRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.95× | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $53.7M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $52.5M | — |
| 自由现金流率自由现金流/营收 | 127.1% | — |
| 资本支出强度资本支出/营收 | 2.8% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $89.2M | — |
8季度趋势，按日历期对齐
经营现金流NFBKRIGL
| Q4 25 | $53.7M | $22.0M | ||
| Q3 25 | $13.9M | $24.0M | ||
| Q2 25 | $14.1M | $30.5M | ||
| Q1 25 | $9.4M | $-893.0K | ||
| Q4 24 | $31.1M | $14.5M | ||
| Q3 24 | $14.0M | $21.7M | ||
| Q2 24 | $6.9M | $302.0K | ||
| Q1 24 | $4.2M | $-5.0M |
自由现金流NFBKRIGL
| Q4 25 | $52.5M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $13.9M | — | ||
| Q1 25 | $9.2M | — | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $13.7M | — | ||
| Q2 24 | $6.7M | — | ||
| Q1 24 | $3.8M | — |
自由现金流率NFBKRIGL
| Q4 25 | 127.1% | — | ||
| Q3 25 | 34.6% | — | ||
| Q2 25 | 35.7% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | 81.6% | — | ||
| Q3 24 | 43.2% | — | ||
| Q2 24 | 21.1% | — | ||
| Q1 24 | 12.1% | — |
资本支出强度NFBKRIGL
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 1.4% | — |
现金转化率NFBKRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 1.29× | 0.86× | ||
| Q2 25 | 1.48× | 0.51× | ||
| Q1 25 | 1.20× | -0.08× | ||
| Q4 24 | 2.76× | 1.01× | ||
| Q3 24 | 2.14× | 1.75× | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
